363 related articles for article (PubMed ID: 7841033)
1. The role of p53 inactivation in human cervical cell carcinoma development.
Miwa K; Miyamoto S; Kato H; Imamura T; Nishida M; Yoshikawa Y; Nagata Y; Wake N
Br J Cancer; 1995 Feb; 71(2):219-26. PubMed ID: 7841033
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.
Fujita M; Inoue M; Tanizawa O; Iwamoto S; Enomoto T
Cancer Res; 1992 Oct; 52(19):5323-8. PubMed ID: 1327506
[TBL] [Abstract][Full Text] [Related]
3. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
5. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
6. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours.
Crook T; Wrede D; Tidy JA; Mason WP; Evans DJ; Vousden KH
Lancet; 1992 May; 339(8801):1070-3. PubMed ID: 1349102
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix.
Kessis TD; Slebos RJ; Han SM; Shah K; Bosch XF; Muñoz N; Hedrick L; Cho KR
Am J Pathol; 1993 Nov; 143(5):1398-405. PubMed ID: 8238255
[TBL] [Abstract][Full Text] [Related]
8. Mutations of p53 and human papillomavirus infection in cervical carcinoma.
Paquette RL; Lee YY; Wilczynski SP; Karmakar A; Kizaki M; Miller CW; Koeffler HP
Cancer; 1993 Aug; 72(4):1272-80. PubMed ID: 8393371
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association.
Chung TK; Cheung TH; Wang VW; Yu MY; Wong YF
Gynecol Obstet Invest; 2001; 52(2):98-103. PubMed ID: 11586036
[TBL] [Abstract][Full Text] [Related]
10. HPV infection in cervical-cancer cases in Russia.
Samoylova EV; Shaikhaiev GO; Petrov SV; Kisseljova NP; Kisseljov FL
Int J Cancer; 1995 May; 61(3):337-41. PubMed ID: 7729945
[TBL] [Abstract][Full Text] [Related]
11. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix.
Saegusa M; Takano Y; Hashimura M; Shoji Y; Okayasu I
Cancer; 1995 Dec; 76(11):2297-303. PubMed ID: 8635035
[TBL] [Abstract][Full Text] [Related]
12. Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers.
Szarka K; Veress G; Juhász A; Kónya J; Sápy T; Soós G; Hernádi Z; Gergely L
Anticancer Res; 2000; 20(3B):2161-7. PubMed ID: 10928171
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of microsatellite instability in patients with cervical carcinomas.
Rodriguez JA; Barros F; Carracedo A; Mugica-van Herckenrode CM
Diagn Mol Pathol; 1998 Oct; 7(5):276-82. PubMed ID: 9990486
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer.
Chen CA; Chen TM; Wu CC; Chang CF; Hsieh CY
J Cancer Res Clin Oncol; 1994; 120(11):678-82. PubMed ID: 7962045
[TBL] [Abstract][Full Text] [Related]
15. "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases.
Stenzel A; Semczuk A; Rózyńskal K; Jakowicki J; Wojcierowski J
Pathol Res Pract; 2001; 197(9):597-603. PubMed ID: 11569923
[TBL] [Abstract][Full Text] [Related]
16. Genomic organization of human papillomavirus type 18 in cervical cancer specimens.
Kitagawa K; Yoshikawa H; Onda T; Kawana T; Taketani Y; Yoshikura H; Iwamoto A
Jpn J Cancer Res; 1996 Mar; 87(3):263-8. PubMed ID: 8613428
[TBL] [Abstract][Full Text] [Related]
17. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva.
Milde-Langosch K; Albrecht K; Joram S; Schlechte H; Giessing M; Löning T
Int J Cancer; 1995 Nov; 63(5):639-45. PubMed ID: 7591279
[TBL] [Abstract][Full Text] [Related]
18. Physical status and expression of HPV genes in cervical cancers.
Park JS; Hwang ES; Park SN; Ahn HK; Um SJ; Kim CJ; Kim SJ; Namkoong SE
Gynecol Oncol; 1997 Apr; 65(1):121-9. PubMed ID: 9103401
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus and cervical cancer: failure to detect a direct association or an interaction with human papillomaviruses.
Thompson CH; Rose BR; Elliott PM
Gynecol Oncol; 1994 Jul; 54(1):40-6. PubMed ID: 8020838
[TBL] [Abstract][Full Text] [Related]
20. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix.
Yamashita T; Yaginuma Y; Saitoh Y; Kawai K; Kurakane T; Hayashi H; Ishikawa M
Carcinogenesis; 1999 Sep; 20(9):1733-6. PubMed ID: 10469618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
